Latest News - Zoetis
Top Corporates Hub
Zoetis
Neogen Soars 4% as Q1 Revenue Beat and Raised Guidance Show “Encouraging Progress”
07.10.2026 13:34
Key TakeawaysNeogen shares jumped 4% after fiscal first-quarter revenue of $222. 8 million beat the $208.
Zoetis (ZTS) Has a Huge Animal Health Moat. Is It Starting to Crack?
02.10.2026 02:49
Zoetis Inc. (NYSE:ZTS) has built one of the strongest franchises in animal health. Its products are used by veterinarians around the world; its portfolio spans medicines, vaccines, and diagnostics, and its research capabilities have helped establish entire categories of treatment. But a moat is only valuable if it protects market share and pricing power when […]
Zoetis: Priced For The Worst, Worth Buying
30.09.2026 06:31
Zoetis (ZTS) stock: why shares fell 71% and whatâs next. Margin strength, pipeline vs. 2030+ patent risks, and $113 fair value.
Zoetis (NYSE:ZTS) Looks Like a Decent Value Stock
25.09.2026 09:21
Zoetis (ZTS) screens as decent value: low P/E, strong 9/10 profitability, solid ROIC, and a sustainable dividend, though growth and leverage are risks.
Zoetis: The Worst May Be Priced In
18.09.2026 10:14
Zoetis is still generating the bigger part of its revenue in the United States, the picture for the overall market is different. Read why ZTS stock is a buy.
Zoetis (ZTS) Stock Fair Value Falls After Mixed Analyst Cuts And Softer Growth Views
18.09.2026 08:13
Zoetis is back in focus after analysts cut their fair value estimate from US$114.76 to US$96.00, a reduction of around 16% that resets expectations around what the stock might be worth. This shift lines up with more mixed analyst commentary, where many firms are trimming price targets and some are also dialing back their ratings as they reassess clinic trends, competition and pricing. Read on to see what is driving the updated narrative and how you can track the next moves in Zoetis. Stay...
Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales
18.09.2026 05:02
Zoetis (NYSE:ZTS) executives said the company remains confident in its previously issued guidance despite pressure in the U.S. companion-animal market, citing a weaker pet-care environment and intensified competition in dermatology and parasiticides. Speaking at a Morgan Stanley conference, CEO Kri
Zoetis: Companion Animal Weakness Keeps Me On The Sidelines
17.09.2026 07:20
Zoetis (ZTS) outlook: Q2 2026 revenue flat, U.S. companion animal sales -11%.
Zoetis: An Undervalued Compounder Hiding In Plain Sight
17.09.2026 05:52
Zoetis faces near-term pressure from weaker US companion animal demand, increased competition, and margin compression. Learn more about ZTS stock now.
Zoetis (NYSE:ZTS): A Quality Dividend Stock for Dividend Investors
14.09.2026 10:10
Zoetis (ZTS) passes a Best Dividend screen with a 7/10 dividend rating, strong profitability, low payout ratio, and a value tilt.
Zoetis (NYSE:ZTS) Offers Value and Quality in One Attractive Package
01.09.2026 10:51
Zoetis (ZTS) emerges from decent value screen with low P/E, high profitability, and strong returns. Growth moderates, leverage noted. Learn more.
Phibro Animal Health: Zoetis Integrated And Better Cash Flow Ahead
30.08.2026 08:30
PAHCâs Zoetis MFA acquisition boosts animal-health growth via vaccines and companion animals. Click for more on PAHC stock.
Zoetis: A Solid Long-Term Buy After Harsh Drawdown
18.08.2026 04:38
Despite aggressive competitor promotions, Zoetis protects industry-leading profitability. Click here to find out why ZTS stock is a Buy.
Zoetis: Another Bad Quarter, Some Value Trap Risk But Shares Still Cheap
16.08.2026 08:45
Zoetisâ mixed Q2 earnings and lowered guidance hit margin of safety, but long-term upside remains. Click for more on ZTS stock.
ZTS Q2 Deep Dive: Leadership Shifts and Competitive Pressures Shape Guidance
10.08.2026 03:25
Animal health company Zoetis (NYSE:ZTS) fell short of the market’s revenue expectations in Q2 CY2026, with sales flat year on year at $2.47 billion. The company’s full-year revenue guidance of $9.22 billion at the midpoint came in 5.4% below analysts’ estimates. Its non-GAAP profit of $1.87 per share was 1% above analysts’ consensus estimates.
Elanco Animal Health Q2 Earnings Call Highlights
08.08.2026 06:03
Elanco Animal Health (NYSE:ELAN) reported second-quarter 2026 revenue of $1.368 billion, up 10% on a reported basis and 8% organically in constant currency, as demand for new pet-health products and strength in U.S. farm animal operations supported growth. Chief Executive Officer Jeff Simmons said
Zoetis (ZTS) Following Earnings And Guidance Cut With A Valuation Question
07.08.2026 16:19
Zoetis earnings, guidance cut and new CFO/COO appointment grab investor attention Zoetis (ZTS) is in focus after reporting second quarter 2026 results that beat earnings per share expectations but came with flat sales, a cut to full year guidance and the appointment of a new CFO/COO. See our latest analysis for Zoetis. The Zoetis share price has reacted positively to the latest earnings and leadership news, with a 1-day share price return of 3.87% and short term gains contrasting with a...
ZTS Q2 Earnings Call Flags Deeper Companion Animal Pressure
07.08.2026 14:00
Zoetis cuts its 2026 outlook as weaker vet traffic, price sensitivity and competition pressure in Companion Animal, while promotions aim to defend share.